azacitidine has been researched along with Allergic Encephalomyelitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bendtzen, K; Coco, M; Di Marco, R; Di Rosa, M; Fagone, P; Magro, G; Malaguarnera, L; Mammana, S; Mangano, K; Meroni, PL; Nicoletti, F; Quattrocchi, C | 1 |
| Chan, MW; Chang, CB; Suen, JL; Sun, J; Tung, CH; Wu, SF | 1 |
2 other study(ies) available for azacitidine and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Hypomethylating agent 5-aza-2'-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models.
Topics: Animals; Anti-Inflammatory Agents; Azacitidine; Cytokines; Decitabine; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Mice; Multiple Sclerosis; T-Lymphocytes, Regulatory | 2014 |
Low-dose 5-aza-2'-deoxycytidine pretreatment inhibits experimental autoimmune encephalomyelitis by induction of regulatory T cells.
Topics: Animals; Azacitidine; Decitabine; DNA Modification Methylases; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Mice, Inbred C57BL; Mice, Transgenic; Mycobacterium tuberculosis; Myelin-Oligodendrocyte Glycoprotein; Spinal Cord; Spleen; T-Lymphocytes, Regulatory | 2014 |